WO2021008338A1 - 极光激酶抑制剂及其用途 - Google Patents

极光激酶抑制剂及其用途 Download PDF

Info

Publication number
WO2021008338A1
WO2021008338A1 PCT/CN2020/098775 CN2020098775W WO2021008338A1 WO 2021008338 A1 WO2021008338 A1 WO 2021008338A1 CN 2020098775 W CN2020098775 W CN 2020098775W WO 2021008338 A1 WO2021008338 A1 WO 2021008338A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
compound
methylpiperidine
chloro
fluoro
Prior art date
Application number
PCT/CN2020/098775
Other languages
English (en)
French (fr)
Inventor
谢雨礼
樊后兴
Original Assignee
微境生物医药科技(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 微境生物医药科技(上海)有限公司 filed Critical 微境生物医药科技(上海)有限公司
Priority to MX2021013981A priority Critical patent/MX2021013981A/es
Priority to BR112021023765A priority patent/BR112021023765A2/pt
Priority to EP20840146.3A priority patent/EP4001276A4/en
Priority to CN202080005314.4A priority patent/CN114072400B/zh
Priority to AU2020314910A priority patent/AU2020314910A1/en
Priority to JP2022502476A priority patent/JP2022541467A/ja
Priority to KR1020217036790A priority patent/KR20220035031A/ko
Priority to CA3142069A priority patent/CA3142069A1/en
Publication of WO2021008338A1 publication Critical patent/WO2021008338A1/zh
Priority to US17/200,854 priority patent/US20210198261A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present invention belongs to the field of medicinal chemistry, and more specifically, to a new compound with Aurora Kinase inhibitory effect, a preparation method thereof, and application of the compound in the preparation of antitumor drugs.
  • Aurora kinase is a new type of threonine/serine protein kinase, which plays a vital role in important mitotic processes such as centrosome replication, bipolar spindle formation, chromosome rearrangement and chromosome checkpoint monitoring. [Cancer Metastasis Rev.,2003,22,451].
  • Aurora-A is located around the centrosome in the early stage of division, the microtubules near the spindle in the middle stage, and the polar microtubules in the later and terminal stages.
  • Aurora-B is located in the centromeric region of the chromosome in the early stage of mitosis, and moves from the centromere to the microtubule in the late stage. Aurora-B regulates centromere function, chromosome arrangement and separation, spindle detection function, and cytokinesis [Mol. Cancer Ther., 2009, 8, 2046-2056].
  • Aurora-C is expressed at high levels in the testis and may play a special role in male animals [Proc Natl Acad Sci USA, 2002, 99(24): 15440-15445.].
  • Aurora-A coding gene is located at 20q13.2, which is ubiquitously amplified in many tumors, such as breast cancer, colon cancer, ovarian cancer and thyroid cancer.
  • the ectopic high expression of Aurora-A in vitro leads to cells showing various cancer cell characteristics such as centrosome amplification, aneuploidy, chromosomal instability, and telomere extension[J.Cell Sci.,2007,120,2987] .
  • Aurora-A's own expression, or activation of its partner TPX-2 is related to chromosomal instability in human cancer cells.
  • Aurora-A can also interfere with the functions of important tumor suppressors and pro-apoptotic proteins such as p53. Among them, Aurora-A interferes with the normal function of p53 through phosphorylation of Ser215. It can also phosphorylate the Ser315 site of p53 and cause p53 degradation.
  • Aurora-B is a molecule of chromosomal passenger protein (CPC) and a core member of CPC. Aurora-B participates in mitosis mainly through phosphorylation of substrates, the main substrates include: INCENP, CENP-A, Survivin, etc. Overexpression of Aurora-B enhances the oncogene ras signal transduction pathway.
  • CPC chromosomal passenger protein
  • LY-3295668 is an Aurora-A kinase inhibitor containing a pyridine main ring [WO2016077161], currently in phase 1 clinical phase.
  • the structural formula of LY-3295668 is as follows:
  • LY-3295668 and other Aurora-A kinase inhibitors have some shortcomings.
  • Aurora kinase activity is not high enough, oral absorption properties are poor, and anti-tumor activity in vivo needs to be improved. Therefore, in view of the existing problems of Aurora kinase inhibitors, it is of great significance to find new Aurora inhibitors with stronger in vitro and in vivo activities.
  • the present invention aims to provide a novel Aurora Kinase inhibitor whose structure is represented by formula (1), or an optical isomer or a pharmaceutically acceptable salt thereof:
  • R 1 is aryl, heteroaryl,
  • the aryl or heteroaryl group may be substituted by 1-3 of the following groups: halogen, C1-C3 alkyl, C1-C3 alkoxy, halogen substituted C1-C3 alkyl and halogen substituted C1-C3 alkane Oxy;
  • R 2 is H or methyl
  • R 3 is H or F
  • W is Wherein R a is H, C1-C3 alkyl or C3-C6 cycloalkyl group, R b is H, C1-C3 alkyl or C3-C6 cycloalkyl group; and
  • L is CH 2 , CO, CD 2 , CH(Me), C(Me) 2 , When W is And R b is H, C2-C3 alkyl or C3-C6 cycloalkyl; or L is CO, CD 2 , CHMe, C(Me) 2 , When W is And when R b is methyl.
  • R 1 is Where X is NH, O or S, R c and Rd are independently H, halogen, C1-C3 alkyl, C1-C3 alkoxy, halogen-substituted C1-C3 alkyl, or halogen-substituted C1-C3 alkoxy.
  • R 1 is
  • W is the following group:
  • L is CH 2 , CO, CD 2 , CH(Me), C(Me) 2 , When W is ⁇ ; or L is CO, CD 2 , CHMe, C(Me) 2 , When W is Time.
  • the compound has one of the structures listed in Table 1 below:
  • Another object of the present invention is to provide a pharmaceutical composition, which contains a pharmacologically acceptable excipient or carrier, and the compound of general formula (1) of the present invention, or each of its optical isomers, and pharmacologically Acceptable salt is used as the active ingredient.
  • Another object of the present invention is to provide the application of the above-mentioned compound of the present invention, or each of its optical isomers, and pharmaceutically acceptable salts in the preparation of Aurora-related diseases, especially anti-tumor drugs.
  • the compounds of Table 1 described above can be synthesized using standard synthesis techniques or well-known techniques and methods combined in the text. In addition, the solvent, temperature and other reaction conditions mentioned here can be changed.
  • the starting materials used for the synthesis of the compounds of Table 1 can be synthesized or obtained from commercial sources such as, but not limited to, Aldrich Chemical Co. (Milwaukee, Wis.) or Sigma Chemical Co. (St. Louis, Mo.).
  • the compounds described herein and other related compounds with different substituents can be synthesized using well-known techniques and raw materials, including those found in March, ADVANCED ORGANIC CHEMISTRY 4 th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4 th Ed., Vols. A and B (Plenum 2000, 2001), Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3 rd Ed., (Wiley 1999).
  • the general method of compound preparation can be changed by using appropriate reagents and conditions for introducing different groups in the molecular formula provided herein.
  • the compounds described herein are according to methods well known in the art. However, the conditions of the method, such as reactants, solvents, bases, amounts of compounds used, reaction temperature, time required for the reaction, etc. are not limited to the following explanations.
  • the compounds of the present invention can also be conveniently prepared by combining various synthetic methods described in this specification or known in the art, and such combinations can be easily performed by those skilled in the art to which the present invention belongs.
  • the present invention also provides a method for preparing the compound shown in Table 1, which is prepared by the following method A or method B:
  • Method A includes the following steps: First, compound A and compound B are reacted under basic conditions in the presence of a metal palladium catalyst and ligand to form compound C, and compound C is removed from the protective group of Boc under acidic conditions to obtain compound D, compound D and R 1 -LX reaction produces E, and finally compound E undergoes ester hydrolysis under acidic or basic conditions to obtain target compound 1(a).
  • R 1, R 2, R 3, R a and L are defined above, X is Br, Cl, OTf, etc. or OH groups.
  • Method B includes the following steps: first, compound F and compound B react to form compound G, then compound G and compound H react under basic conditions in the presence of a metal palladium catalyst and ligand to form compound I, and finally compound I under strongly acidic conditions
  • the following ester hydrolysis and the removal of the Boc protecting group yield the target compound 1(b).
  • R 1, R 2, R 3, R a and L are defined above, X is Br, Cl, OTf, etc. or OH groups.
  • the term "pharmaceutically acceptable salt” refers to a form of a compound that does not cause important irritation to the administered organism and does not cause the biological activity and properties of the compound to disappear.
  • the salt of the compound of the present invention refers to a salt commonly used in the field of organic chemistry.
  • the base-added salt of the carboxy group when it has a carboxyl group, or the amino group or basic heterocyclic group when it has an amino group or a basic heterocyclic group can be cited.
  • the salt of the cyclic acid addition salt can be cited.
  • the base-added salt examples include alkali metal salts such as sodium salt and potassium salt; for example, alkaline earth metal salts such as calcium salt and magnesium salt; for example, ammonium salt; for example, trimethylamine salt, triethylamine salt, dicyclohexylamine salt, Organic amine salts such as ethanolamine salt, diethanolamine salt, triethanolamine salt, procaine salt, N,N'-dibenzylethylenediamine salt, etc.
  • alkali metal salts such as sodium salt and potassium salt
  • alkaline earth metal salts such as calcium salt and magnesium salt
  • ammonium salt for example, trimethylamine salt, triethylamine salt, dicyclohexylamine salt
  • Organic amine salts such as ethanolamine salt, diethanolamine salt, triethanolamine salt, procaine salt, N,N'-dibenzylethylenediamine salt, etc.
  • alkali-added salt examples include inorganic acid salts such as hydrochloride, sulfate, nitric acid, and phosphate; for example, acetate, formate, maleate, fumarate, citrate, and oxalic acid.
  • Organic acid salts such as salt and ascorbate; for example, sulfonates such as methanesulfonate, phenyl cyclate, and p-toluenesulfonate.
  • references to pharmaceutically acceptable salts include solvent addition forms or crystalline forms, especially solvates or polymorphs.
  • Solvates contain stoichiometric or non-stoichiometric solvents, and are selectively formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, etc.
  • a hydrate is formed when the solvent is water, or an alcoholate is formed when the solvent is ethanol.
  • the solvates of the compounds of Table 1 are conveniently prepared or formed according to the methods described herein.
  • the hydrate of the compound in Table 1 is conveniently prepared by recrystallization from a mixed solvent of water/organic solvent.
  • the organic solvent used includes, but is not limited to, dioxane, tetrahydrofuran, ethanol or methanol.
  • the compounds mentioned here can exist in unsolvated and solvated forms. In summary, for the purposes of the compounds and methods provided herein, the solvated form is considered equivalent to the unsolvated form.
  • the compounds of Table 1 are prepared in different forms, including, but not limited to, amorphous, pulverized, and nano-particle size forms.
  • the compounds in Table 1 include crystalline forms and may also be polymorphic forms.
  • Polymorphs include different lattice arrangements of the same elemental composition of the compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal form, optical and electrical properties, stability and solubility. Different factors such as recrystallization solvent, crystallization rate and storage temperature may cause a single crystal form to dominate.
  • the compounds of Table 1 have one or more stereocenters, and therefore appear as racemates, racemic mixtures, single enantiomers, diastereomeric compounds, and single diastereomers.
  • the asymmetric centers that can exist depend on the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and all possible mixtures of optical isomers and diastereomers and pure or partially pure compounds are included within the scope of the present invention. The present invention is meant to include all such isomeric forms of these compounds.
  • the present invention provides a method for treating Aurora kinase-mediated disorders, the method comprising the step of administering a compound of the present invention, or a pharmaceutically acceptable composition thereof, to a patient in need .
  • Cancers that can be treated with the compounds of the present invention include, but are not limited to, hematological malignancies (leukemia, lymphoma, myeloma, including multiple myeloma, myelodysplastic syndrome, and myelodysplastic syndrome) and solid tumors (cancers such as prostate, breast , Lung, colon, pancreas, kidney, ovary and soft tissue cancer and osteosarcoma, and stromal tumor).
  • hematological malignancies leukemia, lymphoma, myeloma, including multiple myeloma, myelodysplastic syndrome, and myelodysplastic syndrome
  • solid tumors cancers such as prostate, breast , Lung, colon, pancreas, kidney, ovary and soft tissue cancer and osteosarcoma, and stromal tumor.
  • the compound of the present invention and its pharmaceutically acceptable salt can be prepared into various preparations, which contain a safe and effective amount of the compound of the present invention or its pharmaceutically acceptable salt and a pharmacologically acceptable excipient or carrier .
  • the "safe and effective amount” refers to: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects.
  • the safe and effective amount of the compound is determined according to the age, condition, and course of treatment of the subject to be treated.
  • “Pharmaceutically acceptable excipient or carrier” refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use, and must have sufficient purity and sufficiently low toxicity . "Compatibility” here means that each component of the composition can be blended with the compound of the present invention and between them without significantly reducing the efficacy of the compound.
  • Examples of pharmacologically acceptable excipients or carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
  • cellulose and its derivatives such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.
  • gelatin such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose a
  • the compound of the present invention when administered, it can be administered orally, rectally, parenterally (intravenous, intramuscular, or subcutaneous), or locally.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or mixed with the following ingredients: (a) fillers or compatibilizers, for example, Starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; (c) humectant, For example, glycerin; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) Absorption accelerators, such as quaternary amine compounds; (g) wetting agents, such as cetyl alcohol and gly
  • Solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be prepared with coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the active compound or the release of the compound in such a composition may be released in a certain part of the digestive tract in a delayed manner. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microcapsules with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • the liquid dosage form may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-Butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
  • composition may also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents and perfumes.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents and perfumes.
  • the suspension may contain suspending agents, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • suspending agents for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • composition for parenteral injection may contain physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
  • the dosage form of the compound of the present invention for topical administration includes ointment, powder, patch, spray and inhalant.
  • the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required if necessary.
  • the compound of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds.
  • a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage is the pharmaceutically effective dosage considered to be administered.
  • the daily administration dose is usually 1 to 1000 mg, preferably 10 to 500 mg.
  • the specific dosage should also consider factors such as the route of administration, the patient's health status, etc., which are within the skill range of a skilled physician.
  • the melting point was measured by the X-4 melting point instrument, the thermometer was not calibrated; 1 H-NMR was recorded by the Varian Mercury 400 nuclear magnetic resonance instrument, and the chemical shift was expressed in ⁇ (ppm); the silica gel used for separation was not specified, it was 200-300 For the purpose, the ratio of eluent is volume ratio.
  • ACN stands for acetonitrile
  • Ar stands for argon
  • CBr 4 stands for carbon tetrabromide
  • CDCl 3 stands for deuterated chloroform
  • CD 3 OD stands for deuterated methanol
  • DCM stands for dichloromethane
  • DIPEA stands for dichloromethane Isopropyl ethylamine
  • Diox stands for 1,4-dioxane
  • DMF stands for dimethylformamide
  • DMSO stands for dimethyl sulfoxide
  • EA stands for ethyl acetate
  • EDCl stands for 1-(3-dimethylamino) Propyl)-3-ethylcarbodiimide hydrochloride
  • h stands for hour
  • HOBt stands for 1-hydroxybenzotriazole
  • K 2 CO 3 stands for potassium carbonate
  • KI stands for potassium iodide
  • K 3 PO 4 stands for potassium phosphate
  • LC-MS stands for liquid phase
  • LC/MS detects that the reaction is complete, add water (100mL) to precipitate solids, filter with suction, wash the filter cake with water (20mLx2) twice, then add PE (50mL) to make a slurry, filter with suction, wash the filter cake with PE (20mLx2) twice, dry Dry the initial product 1-(3-chloro-2-fluorophenylbenzyl)-4-((3-fluoro-6-(thiazol-2-ylamino)pyridin-2-yl)methyl)-2-methyl Methyl piperidine-4-carboxylate (935 mg, yield 100%), directly cast to the next step, ESI-MS m/z: 510.2 [M+H] + .
  • the target compound was obtained by using the synthetic method in Example 1.
  • LC/MS detects that the reaction is complete, add water (100mL) to precipitate solids, filter with suction, wash the filter cake with water (20mL*2) twice, then add PE (50mL) to make a slurry, filter with suction, and wash the filter cake with PE (20mL*2) Twice, dry to obtain the initial product 1-((3-chloro-2-fluorophenyl)methyl-d2)-4-((3-fluoro-6-(thiazol-2-ylamino)pyridine-2- (Yl)methyl)-2-methylpiperidine-4-carboxylic acid methyl ester (931 mg, yield 100%), directly cast to the next step, ESI-MS m/z: 509.2 [M+H] + .
  • the target compound was obtained by using the synthetic method in Example 1.
  • the in vitro inhibitory activity of the above compounds against Aurora kinase activity was determined by the Caliper Mobility Shift Assay method.
  • the compounds were diluted three-fold sequentially starting from 10 ⁇ M to obtain a total of 10 concentrations.
  • the enzyme and kinase reaction solution (20 mM HEPES, pH 7.5, 0.01% Triton X-100) were mixed, and then the compound was added in gradient dilutions. Incubate at room temperature for 10 minutes to allow the compound and enzyme to fully bind. Then add FAM-labeled polypeptide as a substrate to perform a kinase reaction at 25°C. After a certain period of time, add a stop solution to stop.
  • the above data shows that in the compound of general formula (1), when the -L- group is changed from CH 2 to a group of appropriate size, such as CD 2 , and/or when W is
  • the compound has very strong Aurora-A kinase activity, while the Aurora-B kinase activity and the anti-proliferation activity of H1975 cells are greatly improved.
  • the activity of each optical isomer of the compound of the present invention is different.
  • the activity of compound 1-1 is stronger than that of racemic compound 1.
  • the activity of each optical isomer of other compounds of the present invention can be tested by the same method. There are more active optically active isomers.
  • Human lung cancer H1975 cells are routinely cultured in a 1640 containing 10% fetal bovine serum in a 37°C, 5% CO 2 incubator. After passage, when the cells reach the required amount, the cells are digested and collected. 8 ⁇ 10 6 H1975 cells were injected into the left armpit of each nude mouse. After the tumor grew to 80 mm 3 , the animals were randomly divided into groups to start the administration. Respectively 1) solvent control group, 6 rats; 2) LY-3295668 group, compound 13 group and compound 23 group, 6 rats in each group.
  • the solvent control group the solvent of 5% DMSO+45%PEG400+50% water was administered once a day; the LY-3295668 group, compound 13 group and compound 23 group were given a 6mg/mL compound solution 0.1mL/10g (60mg/kg/ day).
  • the tumor volume was measured every two days, the body weight of the mice was measured, and the nude mice were sacrificed on the 21st day of administration. Calculate the relative tumor volume (RTV), relative tumor growth rate (T/C) and tumor growth inhibition rate, and perform statistical testing.
  • RTV relative tumor volume
  • T/C relative tumor growth rate
  • T/C tumor growth inhibition rate
  • compound 13 has significantly enhanced anti-tumor activity in vivo, indicating that in the compound of general formula (1), when the -L- group is changed from CH 2 to an appropriate size group Group replaced, such as CD 2 , and/or, when W is The anti-tumor activity of the compound in vivo is greatly improved. This is of great significance for targeting aurora kinase to treat tumors.
  • Human lung cancer NCI-H69 cells are routinely cultured in 1640 containing 10% fetal bovine serum in a 37°C, 5% CO 2 incubator. After passage, when the cells reach the required amount, the cells are digested and collected. 1 ⁇ 10 7 H69 cells were injected into the left back of each nude mouse. After the tumor grew to about 290 mm 3 , the animals were randomly divided into groups to start administration. They are 1) solvent control group with 8 animals; 2) LY-3295668 group, compound 1-1 low-dose group, compound 1-1 medium-dose group and compound 1-1 high-dose group with 8 animals in each group.
  • the solvent control group was given 0.5% MC solvent twice a day; LY-3295668 group, compound 1-1 low-dose group, compound 1-1 medium-dose group and compound 1-1 high-dose group were given the compound solution 0.1mL/10g (Twice a day).
  • the tumor volume was measured every two days, the body weight of the mice was measured, and the nude mice were sacrificed on the 21st day of administration. Calculate the relative tumor volume (RTV), relative tumor growth rate (T/C) and tumor growth inhibition rate, and perform statistical testing.
  • RTV relative tumor volume
  • T/C relative tumor growth rate
  • T/C tumor growth inhibition rate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及一类新型吡啶类化合物及其制备方法和用途。具体地，本发明涉及式(1)所示的化合物及其制备方法，以及式(1)化合物及其药学上可接受的盐作为极光激酶(Aurora Kinase)抑制剂在抗肿瘤药物制备中的用途。

Description

极光激酶抑制剂及其用途
本申请要求申请日为2019年7月16日的中国专利申请CN2019106430612的优先权。本申请引用上述中国专利申请的全文。
技术领域
本发明属涉及药物化学领域，更具体而言，涉及具有极光激酶(Aurora Kinase)抑制作用的新化合物，及其制备方法和该类化合物在抗肿瘤药物制备中的用途。
背景技术
极光激酶(Aurora kinase)是一类新型的苏氨酸/丝氨酸蛋白激酶，在中心体复制、两极纺锤体形成、染色体重排和染色体检查点监测等重要的有丝分裂过程中发挥着至关重要的作用[Cancer Metastasis Rev.,2003,22,451]。目前已知人类细胞中存在3种结构和功能高度相关的Aurora激酶亚型：Aurora-A、Aurora-B和Aurora-C。Aurora-A在分裂前期位于中心体周围、中期位于纺锤体附近的微管、后期和末期位于极性微管上。它主要负责中心体的复制和分离、双极纺锤体聚集、有丝分裂的进入和推出、对中心体的成熟和纺锤体的装配起着重要的作用[Nat.Rev.Cancer,2005,5,42]。Aurora-B在有丝分裂早期位于染色体的着丝粒区域，分裂后期则从着丝粒移到微管。Aurora-B调控着丝粒的功能、染色体排列和分离、纺锤体检测功能、胞质分裂[Mol.Cancer Ther.,2009,8,2046-2056]。目前，对Aurora-C研究相对较少，其在有丝分裂中的具体作用并没有明确的定义。Aurora-C在睾丸中高水平表达，可能在雄性动物中起到特殊的作用[Proc Natl Acad Sci USA,2002,99(24):15440-15445.]。
Aurora-A编码基因定位于20q13.2，该区在许多肿瘤中普遍存在扩增，如乳腺癌、结肠癌、卵巢癌和甲状腺癌等。Aurora-A在体外的异位高表达导致细胞显示诸如中心体扩增、非整倍体、染色体不稳定、端粒延长等多种癌细胞特征[J.Cell Sci.,2007,120,2987]。观察发现，Aurora-A自身表达，或者激活搭档TPX-2，与人类癌细胞染色体不稳定有关。此外，Aurora-A还会干扰重要的肿瘤抑制因子及促凋亡蛋白例如p53的功能。其中Aurora-A通过磷酸化Ser215干扰p53的正常功能。它还能磷酸化p53的Ser315位点引起p53的降解。
Aurora-B在17p13.1基因组区域的基因图谱在某些人类癌症区域有变化[J.Clin.Pathol.,2007,60(2):218-221]。Aurora-B的mRNA和蛋白质在大多数主要的肿瘤中存在过 度表达，例如结肠癌；口腔癌、肺癌(非小细胞)。Aurora-B是染色体过客蛋白(CPC)的一分子，也是CPC的核心成员。Aurora-B主要通过磷酸化底物参与有丝分裂，主要底物包括：INCENP、CENP-A、Survivin等。Aurora-B过度表达增强致癌基因ras信号转导通路。
Aurora激酶独特的药理作用机制以及与恶性肿瘤的关系，使得它成为抗肿瘤药物研究的重要靶点，其抑制剂被认为是具有良好开发前景的新型抗肿瘤药物。LY-3295668是一个含吡啶主环的Aurora-A激酶抑制剂[WO2016077161]，现在处于临床1期阶段。LY-3295668的结构式如下：
Figure PCTCN2020098775-appb-000001
然而LY-3295668和其它的Aurora-A激酶抑制剂都有一些缺点，比如Aurora激酶活性不够高，口服吸收性质较差，体内抗肿瘤活性也有待提高。因此针对现有Aurora激酶抑制剂存在的问题，找到具有更强体外活性和体内活性的新型Aurora抑制剂具有重要的意义。
发明内容
本发明旨在提供结构如式(1)所示的新型Aurora Kinase抑制剂，或其光学异构体、药学上可接受的盐：
Figure PCTCN2020098775-appb-000002
式(1)中：
R 1为芳基、杂芳基、
Figure PCTCN2020098775-appb-000003
所述芳基或杂芳基可被1-3个下述基团所取代：卤素、C1-C3烷基、C1-C3烷氧基、卤素取代C1-C3烷基和卤素取代C1-C3烷氧基；
R 2为H或甲基；
R 3为H或F；
W为
Figure PCTCN2020098775-appb-000004
其中R a为H、C1-C3烷基或C3-C6环烷基，R b为H、C1-C3烷基或C3-C6环烷基；和
L为CH 2、CO、CD 2、CH(Me)、C(Me) 2、
Figure PCTCN2020098775-appb-000005
当W为
Figure PCTCN2020098775-appb-000006
Figure PCTCN2020098775-appb-000007
且R b为H、C2-C3烷基或C3-C6环烷基时；或L为CO、CD 2、CHMe、C(Me) 2、
Figure PCTCN2020098775-appb-000008
当W为
Figure PCTCN2020098775-appb-000009
且R b为甲基时。
在另一优先例中，其中所述式(1)中，R 1为
Figure PCTCN2020098775-appb-000010
Figure PCTCN2020098775-appb-000011
其中X为NH、O或S，R c和R d独立为H、卤素、C1-C3烷基、C1-C3烷氧基、卤素取代C1-C3烷基或卤素取代C1-C3烷氧基。
在另一优先例中，其中所述式(1)中，R 1为
Figure PCTCN2020098775-appb-000012
Figure PCTCN2020098775-appb-000013
在另一优先例中，其中所述式(1)中，W为下列基团：
Figure PCTCN2020098775-appb-000014
Figure PCTCN2020098775-appb-000015
Figure PCTCN2020098775-appb-000016
和
L为CH 2、CO、CD 2、CH(Me)、C(Me) 2、
Figure PCTCN2020098775-appb-000017
当W为
Figure PCTCN2020098775-appb-000018
Figure PCTCN2020098775-appb-000019
Figure PCTCN2020098775-appb-000020
时；或L为CO、CD 2、CHMe、C(Me) 2、
Figure PCTCN2020098775-appb-000021
当W为
Figure PCTCN2020098775-appb-000022
时。
通过合成和仔细研究了多类涉及具有极光激酶(Aurora Kinase)抑制作用的新化合物，发明人发现在通式(1)化合物中，当-L-基团从CH 2改变成适当大小的基团所取代，比如CD 2，和/或者，当W是
Figure PCTCN2020098775-appb-000023
基团时，化合物具有极强的Aurora-A激酶活性，同时Aurora-B活性和体内抗肿瘤活性得到大幅提高。
在各种不同实施方式中，化合物具有下表1中所列结构中的一个：
表1:本发明代表性化合物列表：
Figure PCTCN2020098775-appb-000024
Figure PCTCN2020098775-appb-000025
Figure PCTCN2020098775-appb-000026
Figure PCTCN2020098775-appb-000027
本发明的另一个目的是提供了一种药物组合物，它含有药理上可接受的赋形剂或载体，以及本发明的通式(1)合物、或其各光学异构体、药学上可接受的盐做为活性成分。
本发明的再一个目的提供了本发明的上述化合物、或其各光学异构体、药学上可接受盐用于制备治疗Aurora相关的疾病、特别是抗肿瘤药物中的应用。
化合物的合成
下面具体地描述本发明表1化合物的制备方法，但这些具体方法不对本发明构成任何限制。
以上说明的表1化合物可使用标准的合成技术或公知的技术与文中结合的方法来合成。此外，在此提到的溶剂，温度和其他反应条件可以改变。用于表1化合物的合成的 起始物料可以由合成或从商业来源上获得，如，但不限于Aldrich Chemical Co.(Milwaukee，Wis.)或Sigma Chemical Co.(St.Louis，Mo.)。本文所述的化合物和其他具有不同取代基的有关化合物可使用公知的技术和原料来合成，包括发现于March，ADVANCED ORGANIC CHEMISTRY 4 th Ed.，(Wiley 1992)；Carey和Sundberg，ADVANCED ORGANIC CHEMISTRY 4 th Ed.，Vols.A和B(Plenum 2000，2001)，Green和Wuts，PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3 rd Ed.，(Wiley 1999)中的方法。化合物制备的一般方法可通过使用适当的试剂和在此提供的分子式中引入不同基团的条件来改变。
一方面，本文所述的化合物根据工艺中公知的方法。然而方法的条件，例如反应物、溶剂、碱、所用化合物的量、反应温度、反应所需时间等不限于下面的解释。本发明化合物还可以任选将在本说明书中描述的或本领域已知的各种合成方法组合起来而方便的制得，这样的组合可由本发明所属领域的技术人员容易的进行。一方面，本发明还提供了一种所述的表1所示化合物的制备方法，其采用下列方法A或方法B制备：
方法A包含下列步骤：首先化合物A和化合物B在碱性条件下，金属钯催化剂和配体存在下反应生成化合物C，化合物C酸性条件下脱除Boc保护基得到化合物D，化合物D和R 1-L-X反应生成E，最后化合物E在酸性或碱性条件下进行酯水解反应得到目标化合物1(a)。
Figure PCTCN2020098775-appb-000028
上述反应方程式中，R 1、R 2、R 3、R a和L的定义如前所述，X为Br、Cl、OTf或OH等基团。
方法B包含下列步骤：首先化合物F和化合物B反应生成化合物G，接着化合物G和话化合物H在碱性条件下，金属钯催化剂和配体存在下反应生成化合物I，最后化合物I在强酸性条件下进行酯水解并脱除Boc保护基得到目标化合物1(b)。
Figure PCTCN2020098775-appb-000029
上述反应方程式中，R 1、R 2、R 3、R a和L的定义如前所述，X为Br、Cl、OTf或OH等基团。
化合物的进一步形式
术语“药学上可接受的盐”指一种化合物的存在形式，该形式不会引起对给药有机体的重要的刺激，且不会使化合物的生物活性和性质消失。本发明化合物的盐指有机化学领域中所使用的惯用的盐，例如能够列举在具有羧基时的该羧基的碱添加盐、或者具有胺基或碱性杂环基时该胺基或碱性杂环基的酸添加盐的盐类。
作为该碱添加盐，可以列举例如钠盐、钾盐等碱金属盐；例如钙盐、镁盐等碱土金属盐；例如铵盐；例如三甲胺盐、三乙胺盐、二环己胺盐、乙醇胺盐、二乙醇胺盐、三乙醇胺盐、普鲁卡因盐、N,N’-二苄基亚乙基二胺盐等有机胺盐等。
作为该碱添加盐，可以列举例如盐酸盐、硫酸盐、硝酸、磷酸盐等无机酸盐；例如乙酸盐、甲酸盐、马来酸盐、富马酸盐、柠檬酸盐、草酸盐、抗坏血酸盐等有机酸盐；例如甲磺酸盐、苯环酸盐、对甲苯磺酸盐等磺酸盐等。
应理解药学上可接受的盐的参考包括溶剂添加形式或结晶形式，尤其是溶剂化物或多晶型。溶剂化物含有化学计量或非化学计量的溶剂，且是在与药学上可接受溶剂如水，乙醇等，结晶化过程中选择性形成的。当溶剂是水时形成水合物，或当溶剂是乙醇时形成醇化物。表1化合物的溶剂化物按照本文所述的方法，很方便的制得或形成。举例说明，表1化合物的水合物从水/有机溶剂的混合溶剂中重结晶而方便的制得，使用的有机溶剂包括但不限于，二氧杂环乙烷，四氢呋喃，乙醇或甲醇。此外，在此提到的化合物能够以非溶剂化和溶剂化形式存在。总之，对于在此提供的化合物和方法为目的，溶剂化形式被认为相当于非溶剂化形式。
在其他具体实施例中，表1化合物被制备成不同的形式，包括但不限于，无定形，粉碎形和毫微-粒度形式。此外，表1化合物包括结晶型，也可以作为多晶型。多晶型包 括化合物的相同元素组成的不同晶格排列。多晶型通常有不同的X-射线衍射图，红外光谱，熔点，密度，硬度，晶型，光和电的性质，稳定性和溶解性。不同的因素如重结晶溶剂，结晶速率和贮存温度可能引起单一晶型为主导。
在另一个方面，表1化合物有一个或多个立体中心，并因此以消旋体、外消旋混合物、单一对映体、非对映异构体化合物和单一非对映体的形式出现。可以存在的不对称中心，取决于分子上各种取代基的性质。每个这种不对称中心将独立地产生两个旋光异构体，并且所有可能的旋光异构体和非对映体混合物以及纯或部分纯的化合物包括在本发明的范围之内。本发明意味着包括这些化合物的所有这种异构形式。
治疗用途
文中描述的化合物或组合物通常可用于抑制Aurora激酶，因此可用于治疗与Aurora激酶活性相关的一种或多种病症。因此，在某些实施方式中，本发明提供了用于治疗Aurora激酶介导的病症的方法，所述方法包括向有需要的患者施用本发明化合物、或其药学上可接受的组合物的步骤。
可用本发明化合物治疗的癌症包括但不限于，血液恶性肿瘤(白血病、淋巴瘤、骨髓瘤包括多发性骨髓瘤、骨髓异常增生综合症和骨髓增生姓综合症)和实体瘤(癌例如前列腺、乳腺、肺、结肠、胰腺、肾、卵巢以及软组织癌和骨肉瘤，以及间质瘤)等。
给药途径
本发明的化合物及其药学上可接受的盐可制成各种制剂，其中包含安全、有效量范围内的本发明化合物或其药学上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全、有效量”指的是：化合物的量足以明显改善病情，而不至于产生严重的副作用。化合物的安全、有效量根据治疗对象的年龄、病情、疗程等具体情况来确定。
“药学上可以接受的赋形剂或载体”指的是：一种或多种相容性固体或液体填料或凝胶物质，它们适合于人使用，而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能与本发明的化合物以及它们之间相互掺和，而不明显降低化合物的药效。药理上可以接受的赋形剂或载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如
Figure PCTCN2020098775-appb-000030
)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
施用本发明化合物时，可以口服、直肠、肠胃外(静脉内、肌肉内或皮下)、局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型 中，活性化合物与至少一种常规惰性赋形剂(或载体)混合，如柠檬酸钠或磷酸二钙，或与下述成分混合：(a)填料或增容剂，例如，淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸；(b)粘合剂，例如，羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶；(c)保湿剂，例如，甘油；(d)崩解剂，例如，琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠；(e)缓溶剂，例如石蜡；(f)吸收加速剂，例如，季胺化合物；(g)润湿剂，例如鲸蜡醇和单硬脂酸甘油酯；(h)吸附剂，例如，高岭土；和(i)润滑剂，例如，滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠，或其混合物。胶囊剂、片剂和丸剂中，剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备，如肠衣和其它本领域公知的材料。它们可包含不透明剂，并且，这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时，活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外，液体剂型可包含本领域中常规采用的惰性稀释剂，如水或其它溶剂，增溶剂和乳化剂，例知，乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油，特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外，组合物也可包含助剂，如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外，悬浮液可包含悬浮剂，例如，乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液，和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂，或必要时可能需要的推进剂一起混合。
本发明化合物可以单独给药，或者与其他药学上可接受的化合物联合给药。
使用药物组合物时，是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人)，其中施用时剂量为药学上认为的有效给药剂量，对于60kg体重的人而言，日给药剂 量通常为1～1000mg，优选10～500mg。当然，具体剂量还应考虑给药途径、病人健康状况等因素，这些都是熟练医师技能范围之内的。
本发明提到的上述特征，或实施例提到的特征可以任意组合。本案说明书所揭示的所有特征可与任何组合物形式并用，说明书中所揭示的各个特征，可以任何可提供相同、均等或相似目的的替代性特征取代。因此除有特别说明，所揭示的特征仅为均等或相似特征的一般性例子。
在下面的说明中将会详细阐述上述化合物、方法、药物组合物的各个具体方面、特性和优势，使本发明的内容变得十分明了。在此应理解，下述的详细说明及实例描述了具体的实施例，仅用于参考。在阅读了本发明的说明内容后，本领域的技术人员可对本发明作各种改动或修改，这些等价形势同样落于本申请所限定的范围。
所有实施例中，熔点用X-4熔点仪测定，温度计未校正； 1H-NMR用Varian Mercury 400核磁共振仪记录，化学位移以δ(ppm)表示；分离用硅胶未说明均为200-300目，洗脱液的配比均为体积比。
本发明采用下述缩略词：ACN代表乙腈；Ar代表氩气；CBr 4代表四溴化碳；CDCl 3代表氘代氯仿；CD 3OD代表氘代甲醇；DCM代表二氯甲烷；DIPEA代表二异丙基乙基胺；Diox代表1,4-二氧六环；DMF代表二甲基甲酰胺；DMSO代表二甲基亚砜；EA代表乙酸乙酯；EDCl代表1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐；h代表小时；HOBt代表1-羟基苯并三氮唑；K 2CO 3代表碳酸钾；KI代表碘化钾；K 3PO 4代表磷酸钾；LC-MS代表液相-质谱；LiAlD 4代表氘代锂铝氢；LiOH代表氢氧化锂；mL代表毫升；MeOH代表甲醇；min代表分钟；MS代表质谱；NMR代表核磁共振；Pd 2(dba) 3代表三(二亚苄基丙酮)二钯；PE代表石油醚；PPh 3代表三苯基膦；Tf 2O代表三氟甲磺酸酐；Xantphos代表4,5-双二苯基膦-9,9-二甲基氧杂蒽。
具体实施方式
实施例1 1-(3-氯-2-氟苄基)-4-((6-(3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物1)的合成
Figure PCTCN2020098775-appb-000031
1-(叔丁基)4-甲基4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-1,4-双甲酸酯
250mL单口瓶中加入1-(叔丁基)4-甲基4-((6-溴-3-氟吡啶-2-基)甲基)-2-甲基哌啶-1,4-双甲酸酯(5g,11.23mmol，参照专利WO2016077161中的方法合成得到)，2-氨基噻唑(956mg,9.55mmol)，无水磷酸钾(6g,28.08mmol)，Xantphos(650mg,1.123mmol)和Dioxane(100mL)，Ar置换保护后加入Pd 2(dba) 3(514mg,0.562mmol)，Ar保护下升温至回流反应5h。LC-MS监测反应完成后，体系减压浓缩，残留物柱层析纯化(DCM/MeOH＝50/0to 50/1)得黄色固体(4.0g,收率89％)，ESI-MS m/z:465.2[M+H] +。
4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶甲酸甲酯
100mL单口瓶中加入1-(叔丁基)4-甲基4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-1,4-双甲酸酯(4g,8.61mmol)，DCM(20mL)和HCl/Dioxane(22mL,4M,88mmol)，室温下搅拌20h。LC-MS检测反应完成后。反应液浓缩，残留物加入EA(30mL)室温搅拌30min，过滤，干燥，得黄色固体产物(4.1g,收率100％)，ESI-MS m/z:365.2[M+H] +。
1-(3-氯-2-氟苯苄基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-甲酸甲酯
100mL单口瓶中加入4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶甲酸甲酯(800mg,1.83mmol)，1-(溴甲基)-3-氯-2-氟苯(500mg,2.19mmol)，K 2CO 3(1.264g,9.15mmol)，KI(20mg)和ACN(20mL)，室温反应约2h。LC/MS检测反应完全,加水(100mL)析出固体，抽滤，滤饼以水(20mLx2)洗2次后加PE(50mL)打浆，抽滤，滤饼以PE(20mLx2)洗2次，晾干得初产物1-(3-氯-2-氟苯苄基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-甲酸甲酯(935mg,收率100％)，直接投下一步，ESI-MS m/z:510.2[M+H] +。
1-(3-氯-2-氟苄基)-4-((6-(3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸
100mL单口瓶中加入1-(3-氯-2-氟苯苄基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-甲酸甲酯(935mg,1.83mmol)，水(15mL)，浓HCl(15mL)，105℃回流反应约5h。LC/MS检测反应完全，将反应液减压浓缩至干，残留物加ACN(30mL)室温打浆，抽滤，滤饼用ACN(5mL*2)洗涤，晾干得淡黄色粉末状产物(818mg，收率90％)。
1H NMR(400MHz,DMSO-d 6)δ:11.68(s,1H),10.59(s,1H),7.76(t,J＝7.2Hz,1H),7.73-7.68(m,1H),7.61(t,J＝9.2Hz,1H),7.43(d,J＝3.7Hz,1H),7.34(t,J＝7.9Hz,1H),7.01(q,J＝3.9Hz,2H),4.72(d,J＝13.3Hz,1H),4.36(dd,J＝13.6,8.3Hz,1H),3.88(s,2H),3.26-3.21(m,2H),3.09(d,J＝12.9Hz,1H),2.16-1.95(m,4H),1.50(d,J＝6.0Hz,3H)；ESI-MS m/z:493.1[M+H] +。
通过不同的手性原料或者手性分离的方法，可以得到化合物1的四个不同的光学异构体，结构式如下：
Figure PCTCN2020098775-appb-000032
化合物1-1、1-2、1-3和1-4的命名如下：
1-1：(2R,4R)-1-(3-氯-2-氟苄基)-4-((6-(3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸；
1-2：(2S,4S)-1-(3-氯-2-氟苄基)-4-((6-(3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸；
1-3：(2R,4S)-1-(3-氯-2-氟苄基)-4-((6-(3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸；
1-4：(2S,4R)-1-(3-氯-2-氟苄基)-4-((6-(3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸。
本申请中的其它化合物也可以通过同样的方法来分离相应的光学异构体。
实施例2 4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-1-((3-氟吡啶-4-基)甲基)-2-甲基哌啶-4-羧酸(化合物2)的合成
Figure PCTCN2020098775-appb-000033
以4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和4-(溴甲基)-3-氟吡啶为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,DMSO-d 6)δ:12.45(s,1H),11.45(s,1H),8.74(d,J＝1.4Hz,1H),8.54(d,J＝4.9Hz,1H),8.03(t,J＝5.7Hz,1H),7.68(t,J＝9.1Hz,1H),7.50(d,J＝4.0Hz,1H),7.13(q,J＝3.7,3.3Hz,2H),4.71(d,J＝13.3Hz,1H),4.43(dd,J＝13.5,7.9Hz,1H),3.93(s,1H),3.39(dt,J＝14.8,9.1Hz,1H),3.30-3.23(m,2H),3.09(d,J＝13.1Hz,1H),2.08(t,J＝15.2Hz,3H),1.92(d,J＝15.2Hz,1H),1.51(d,J＝6.2Hz,3H)；ESI-MS m/z:460.2[M+H] +。
实施例3 1-((2-氯-3-氟吡啶-4-基)甲基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物3)的合成
Figure PCTCN2020098775-appb-000034
以4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和4-(溴甲基)-2-氯-3-氟吡啶为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,DMSO-d 6)δ:11.22(s,1H),9.82(s,1H),8.39(s,1H),7.68(s,1H),7.57(t,J＝9.1Hz,1H),7.37(d,J＝3.6Hz,1H),6.98-6.89(m,2H),4.76(m,1H),4.41(m,1H),3.89(s,2H),3.23(m,3H),2.13(m,2H),1.82(m,2H),1.36(d,J＝6.4Hz,3H)；ESI-MS m/z:494.1[M+H] +。
实施例4 1-((3-氟-2-(2,2,2-三氟乙氧基)吡啶-4-基)甲基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物4)的合成
Figure PCTCN2020098775-appb-000035
以4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和4-(溴甲基)-3-氟-2-(2,2,2-三氟乙氧基)吡啶为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,Methanol-d 4)δ:7.64(dd,J＝8.3,7.4Hz,1H),7.32-7.27(m,2H),7.23(t,J＝7.9Hz,1H),7.17(dd,J＝7.8,1.5Hz,1H),7.02(d,J＝7.2Hz,1H),6.90-6.86(m,2H),3.84-3.77(m,2H),3.73(s,2H),3.44(t,J＝5.1Hz,2H),2.69(t,J＝5.1Hz,2H),2.64-2.58(m,3H),1.53(d,J＝6.0Hz,3H)；ESI-MS m/z:558.2[M+H] +。
实施例5 1-((5-氯噻吩-2-基)甲基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物5)的合成
Figure PCTCN2020098775-appb-000036
以4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和2-(溴甲基)-5-氯噻吩为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,Methanol-d 4)δ:7.69(t,J＝8.7Hz,1H),7.58(s,1H),7.25(q,J＝9.5,7.5Hz,2H),7.15(dd,J＝9.0,3.0Hz,1H),7.00(dd,J＝30.0,3.5Hz,1H),4.62-4.37(m,2H),3.80(d,J＝26.4Hz,2H),3.39(d,J＝6.4Hz,2H),3.21-3.11(m,1H),2.33-1.98(m,4H),1.45(d,J＝6.0Hz,3H)；ESI-MS m/z:481.1[M+H] +。
实施例6 1-(苯并呋喃-4-基甲基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物6)的合成
Figure PCTCN2020098775-appb-000037
以4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和4-(溴甲基)苯并呋喃为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,DMSO-d 6)δ:7.62(d,J＝7.2Hz,1H),7.50(t,J＝9.1Hz,1H),7.32(d,J＝3.4Hz,1H),7.24(dd,J＝7.1,2.1Hz,1H),7.19-7.11(m,2H),6.89(d,J＝5.1Hz,2H),6.65(d,J＝7.2Hz,1),3.84(d,J＝14.1Hz,1H),3.69(d,J＝14.2Hz,1H),3.05(s,2H),2.77-2.73(m,1H),2.65-2.57(m,1H),2.49-2.42(m,1H),1.84-1.75(m,1H),1.72-1.63(m,2H),1.57(t,J＝11.9Hz,1H),1.16(d,J＝6.0Hz,3H)；ESI-MS m/z:481.2[M+H] +。
实施例7 1-((2,2-二氟苯并[d][1,3]二噁唑-4-基)甲基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物7)的合成
Figure PCTCN2020098775-appb-000038
以4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和4-(溴甲基)-2,2-二氟苯并[d][1,3]二氧杂环戊烯为原料，采用实施例1中的合成方法得到中间体1–((2,2-二氟苯并[d][1,3]二氧杂环戊烯-4-基)甲基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-甲酯甲基。
100mL单口瓶中加入上述中间体(100mg,0.187mmol)，THF(10mL)，H 2O(5mL)和LiOH.H 2O(79mg，1.88mmol)，Ar保护下升至60℃搅拌反应10h，LC-MS监测反应完成后，混合液浓缩至剩余约7.5mL，残留物过反相Flash纯化得目标产物(60mg,收率62％)。
1H NMR(400MHz,DMSO-d 6)δ:7.50(t,J＝9.1Hz,1H),7.32(d,J＝3.4Hz,1H),7.24(dd,J＝7.1,2.1Hz,1H),7.19-7.11(m,2H),6.89(d,J＝5.1Hz,2H),3.94(d,J＝14.1Hz,1H),3.39(d,J＝14.2Hz,1H),3.05(s,2H),2.75-2.71(m,1H),2.61-2.52(m,1H),2.45-2.40(m,1H),1.83-1.79(m,1H),1.75-1.62(m,2H),1.54(t,J＝11.9Hz,1H),1.06(d,J＝6.0Hz,3H)；ESI-MS m/z:521.2[M+H] +。
实施例8 1-((2,2-二氟-2,3-二氢-1H-茚-4-基)甲基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物8)的合成
Figure PCTCN2020098775-appb-000039
以4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和4-(溴甲基)-2,2-二氟-2,3-二氢-1H-茚为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,DMSO-d 6)δ:7.52(t,J＝9.1Hz,1H),7.30(d,J＝3.4Hz,1H),7.23(dd,J＝7.1,2.1Hz,1H),7.19-7.11(m,2H),6.89(d,J＝5.0Hz,2H),5.34-5.21(m,4H),3.94(d,J＝14.1Hz,1H),3.39(d,J＝14.2Hz,1H),3.05(s,2H),2.75-2.71(m,1H),2.61-2.50(m,1H),2.45-2.40(m,1H),1.83-1.79(m,1H),1.75-1.65(m,2H),1.54(t,J＝11.9Hz,1H),1.07(d,J＝6.0Hz,3H)；ESI-MS m/z:517.2[M+H] +。
实施例9 1-(1-(3-氯-2-氟苯基)乙基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸化(合物9)的合成
Figure PCTCN2020098775-appb-000040
以4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和1-(1-溴乙基)-3-氯-2-氟苯为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,DMSO-d 6)δ:12.27(s,1H),11.15(s,1H),7.55(d,J＝8.1Hz,1H),7.49-7.34(m,2H),7.18(t,J＝7.8Hz,1H),7.02(s,1H),6.86(d,J＝8.3Hz,1H),6.67(d,J＝7.3Hz,1H),4.41(m,1H),3.11(d,J＝16.6Hz,2H),3.02(m,2H),2.85(m,1H),1.76-1.52(m,4H),1.30(d,J＝6.7Hz,3H),1.06(q,J＝7.1,6.4Hz,3H)；ESI-MS m/z:507.2[M+H] +。
实施例10 1-(1-(3-氯-2-氟苯基)环丙基)-4–((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物10)的合成
Figure PCTCN2020098775-appb-000041
4–((6-溴-3-氟吡啶-2-基)甲基)-1-(1-(3-氯-2-氟苯基)环丙基)-2-甲基哌啶-4-羧酸甲酯
100mL三口瓶中加入1-(3-氯-2-氟苯基)环丙烷-1-醇(400mg,2.145mmol)，干燥的二氯甲烷(10mL)，DIPEA(692mg,5.362mmol)，Ar保护下降温至-45℃，后滴加Tf 2O(726mg,2.574mmol)的二氯甲烷(10mL)溶液，滴毕，混合液-50-40℃，下搅拌2h。后加入4–((6-溴-3-氟吡啶-2-基(甲基(-2-甲基哌啶-4-羧酸甲酯(444mg,1.287mmol)的乙腈(10mL)溶液，体系升至室温搅拌反应2h。LC-MS监测反应完成后，体系加水(20mL)淬灭，分液，水相用DCM(20mL)萃取，合并有机相浓缩至干，残留物柱层析纯化得产物(284mg,收率43％)，ESI-MS m/z:533.2[M+H] +。
1-(1-(3-氯-2-氟苯基)环丙基)-4–((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸
后以4–((6-溴-3-氟吡啶-2-基)甲基)-1-(1-(3-氯-2-氟苯基)环丙基)-2-甲基哌啶-4-羧酸甲酯和2-氨基噻唑为原料，参照实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,DMSO-d 6)δ:12.11(s,1H),11.02(s,1H),7.57(d,J＝8.1Hz,1H), 7.43-7.33(m,2H),7.15(t,J＝7.8Hz,1H),7.02(s,1H),6.84(d,J＝8.3Hz,1H),6.65(d,J＝7.3Hz,1H),3.41(d,J＝16.6Hz,2H),3.02(m,3H),2.23-1.89(m,4H),1.30(d,J＝6.7Hz,3H),0.75-0.62(m,4H)；ESI-MS m/z:519.2[M+H] +。
实施例11 1-(3-(3-氯-2-氟苯基)氧杂环丁烷-3-基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物11)的合成
Figure PCTCN2020098775-appb-000042
以4–((6-溴-3-氟吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯和3-(3-氯-2-氟苯基)氧杂环丁烷-3-醇为原料，参照实施例10中的合成方法得到中间体4-((6-溴-3-氟吡啶-2-基)甲基)-1-(3-(3-氯-2-氟苯基)氧杂环丁烷-3-基)-2-甲基哌啶-4-羧酸甲酯。
后以上述中间体和2-氨基噻唑为原料，参照实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,CD 3OD)δ:7.46(m,2H),7.35-7.16(m,3H),6.93(dt,J＝8.9,3.3Hz,1H),6.87(t,J＝4.1Hz,1H),4.77(s,1H),4.70-4.47(m,2H),4.31(d,J＝12.2Hz,1H),4.14(d,J＝8.0Hz,1H),3.98(ab,J＝29.9,12.4Hz,1H),3.67(t,J＝11.3Hz,1H),3.17-2.96(m,2H),2.50-2.13(m,3H),2.08-1.95(m,1H),1.89(d,J＝12.4Hz,1H),1.41(d,J＝6.9Hz,3H)；ESI-MS m/z:535.2[M+H] +。
实施例12 1-(3-氯-2-氟苄基)-2-甲基-4-((6-(噻唑-2-基氨基)吡啶-2-基)甲基)哌啶-4-羧酸(化合物12)的合成
Figure PCTCN2020098775-appb-000043
100mL单口瓶中加入3-氯-2-氟苯甲酸(262mg,1.50mmol)，DMF(20mL)，EDCI(431mg,2.25mmol)，HOBt(304mg,2.25mmol)和DIPEA(970mg,7.52mmol)，混合液Ar保护下室温搅拌30min，后加入4–((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐(437mg,1.0mmol)，体系室温搅拌20h。LC-MS监测反应完成后，体系加水(40mL)淬灭，EA(50mL*2)萃取，合并有机相用饱和氯化钠溶液洗涤，浓缩， 残留物柱层析纯化得中间体(365mg,收率70％)。
以上述中间体为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,CD 3OD)δ:7.68(t,J＝9.0Hz,1H),7.62-7.52(m,2H),7.43(dt,J＝12.0,7.9Hz,1H),7.27(d,J＝7.5Hz,1H),7.21(d,J＝4.3Hz,1H),7.12(dd,J＝8.9,3.0Hz,1H),3.73(s,2H),3.22-3.12(m,3H),2.13-1.88(m,4H),1.45(d,J＝6.0Hz,3H)；ESI-MS m/z:475.2[M+H] +。
实施例13 1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物13)的合成
Figure PCTCN2020098775-appb-000044
1-(溴甲基-d2)-3-氯-2-氟苯
100mL三口瓶中加入2-氟-3-氯苯甲酸甲酯(658mg,3.49mmol)，THF(dry,10mL)，冰浴下加LiAlD 4(146mg,3.49mmol)，继续反应约0.5h。TLC检测(PE/EA＝10/1)反应完全，冰浴下加水(20mL)淬灭反应，加饱和氯化钠溶液(20mL)以及EA(20mL*2)萃取，有机相用无水硫酸钠干燥，过滤，旋干得(3-氯-2-氟苯基)甲基-d2-醇，粗品直接投下一步。
100mL单口瓶中加入(3-氯-2-氟苯基)甲基-d2-醇(657mg,4.02mmol)，DCM(20mL)和CBr 4(2g,6.03mmol)，分批加PPh 3(1.371g,5.23mmol)，室温反应约1h。TLC检测(PE/EA＝10/1)反应完全。粗品柱层析(PE,800mL)纯化得无色油状物1-(溴甲基-d2)-3-氯-2-氟苯(921mg,收率100％)。
1H NMR(400MHz,CDCl 3)δ7.34(ddd,J＝8.3,6.9,1.7Hz,1H),7.27(ddd,J＝7.9,6.5,1.7Hz,1H),7.05(td,J＝7.9,1.2Hz,1H)。
1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-甲酸甲酯
100mL单口瓶中加入4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶甲酸甲 酯(800mg,1.83mmol)，1-(溴甲基-d2)-3-氯-2-氟苯(495mg,2.19mmol)，K 2CO 3(1.264g,9.15mmol)，KI(20mg)和ACN(20mL)，室温反应约2h。LC/MS检测反应完全,加水(100mL)析出固体，抽滤，滤饼以水(20mL*2)洗2次后加PE(50mL)打浆，抽滤，滤饼以PE(20mL*2)洗2次，晾干得初产物1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-甲酸甲酯(931mg,收率100％)，直接投下一步，ESI-MS m/z:509.2[M+H] +。
1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸
100mL单口瓶中加入1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-甲酸甲酯(931mg,1.83mmol)，水(15mL)，浓HCl(15mL)，105℃回流反应约5h。LC/MS检测反应完全，将反应液减压浓缩至干，残留物加ACN(30mL)室温打浆，抽滤，滤饼用ACN(5mL*2)洗涤，晾干得淡黄色粉末状产物(815mg，收率90％)。
1H NMR(400MHz,CD 3OD)δ:7.73(t,J＝8.7Hz,1H),7.70-7.55(m,3H),7.36-7.24(m,2H),7.20(dd,J＝8.8,2.9Hz,1H),3.96(s,2H),3.57-3.44(m,2H),3.36(s,1H),2.41-1.96(m,4H),1.53(m,3H)；ESI-MS m/z:495.1[M+H] +。
通过不同的手性原料或者手性分离的方法，可以得到化合物13的四个不同的光学异构体，结构式如下：
Figure PCTCN2020098775-appb-000045
化合物13-1、13-2、13-3和13-4的命名如下：
13-1：(2R,4R)-1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸；
13-2：(2S,4S)-1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸；
13-3：(2R,4S)-1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)- 2-甲基哌啶-4-羧酸；
13-4：(2S,4R)-1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸。
实施例14 1-(3-氯-2-氟苯甲酰基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物14)的合成
Figure PCTCN2020098775-appb-000046
以2-甲基-4–((6-(噻唑-2-基氨基)吡啶-2-基)甲基)哌啶-4-羧酸甲酯盐酸盐和1-(溴甲基)-3-氯-2-氟苯为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,DMSO-d 6)δ:11.88(s,1H),10.79(s,1H),7.74(t,J＝7.2Hz,1H),7.72-7.63(m,2H),7.55(t,J＝9.2Hz,1H),7.41(d,J＝3.7Hz,1H),7.32(t,J＝7.9Hz,1H),7.06(q,J＝3.9Hz,2H),4.73(d,J＝13.3Hz,1H),4.38(dd,J＝13.6,8.3Hz,1H),3.68(s,2H),3.26-3.24(m,2H),3.02(d,J＝12.9Hz,1H),2.15-1.91(m,4H),1.52(d,J＝6.0Hz,3H)；ESI-MS m/z:507.1[M+H] +。
实施例15 1-((3-氯-2-氟苯基)甲基-d2)-2-甲基-4-((6-(噻唑-2-基氨基)吡啶-2-基)甲基)哌啶-4-羧酸(化合物15)的合成
Figure PCTCN2020098775-appb-000047
以1-(叔丁基)4-甲基4-((6-溴吡啶-2-基)甲基)-2-甲基哌啶-1,4-双甲酸酯和2-氨基噻唑为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,CD 3OD)δ:7.78(t,J＝8.7Hz,1H),7.70-7.55(m,3H),7.36-7.24(m,3H),7.23(dd,J＝8.8,2.9Hz,1H),3.92(s,2H),3.57-3.44(m,2H),3.36(m,1H),2.41-1.96(m,4H),1.55(m,3H)；ESI-MS m/z:477.1[M+H] +。
实施例16 1-(3-氯-2-氟苄基)-4-((3-氟-6-((5-甲基噻唑-2-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物16)的合成
Figure PCTCN2020098775-appb-000048
以1-(叔丁基)4-甲基4-((6-溴-3-氟吡啶-2-基)甲基)-2-甲基哌啶-1,4-双甲酸酯和5-甲基-2-氨基噻唑为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,DMSO-d 6)δ:11.66(s,1H),10.59(s,1H),7.76(t,J＝7.2Hz,1H),7.72-7.66(m,2H),7.55(t,J＝9.2Hz,1H),7.34(t,J＝7.9Hz,1H),7.01(m,1H),4.72(d,J＝13.3Hz,1H),4.36(dd,J＝13.6,8.3Hz,1H),3.88(s,2H),3.26-3.21(m,2H),3.09(d,J＝12.9Hz,1H),2.27(s,3H),2.16-1.95(m,4H),1.50(d,J＝6.0Hz,3H)；ESI-MS m/z:508.1[M+H] +。
实施例17 1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-((5-甲基噻唑-2-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物17)的合成
Figure PCTCN2020098775-appb-000049
以4-((3-氟-6-((5-甲基噻唑-2-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和1-(溴甲基-d2)-3-氯-2-氟苯为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,CD 3OD)δ:7.75(t,J＝8.7Hz,1H),7.72-7.56(m,3H),7.28(s,1H),7.20(dd,J＝8.8,2.9Hz,1H),3.96(s,2H),3.57-3.44(m,2H),3.36(s,1H),2.57(s,3H),2.41-1.96(m,4H),1.53(m,3H)；ESI-MS m/z:510.0[M+H] +。
实施例18 1-(3-氯-2-氟苄基)-4-((3-氟-6-((4-甲基噻唑-2-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物18)的合成
Figure PCTCN2020098775-appb-000050
以1-(叔丁基)4-甲基4-((6-溴-3-氟吡啶-2-基)甲基)-2-甲基哌啶-1,4-双甲酸酯和4-甲基-2-氨基噻唑为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,DMSO-d 6)δ:11.64(s,1H),10.53(s,1H),7.73(t,J＝7.2Hz,1H),7.70-7.66(m,2H),7.55(t,J＝9.2Hz,1H),7.34(t,J＝7.9Hz,1H),6.56(s,1H),4.68(d,J＝13.3Hz,1H),4.37(dd,J＝13.6,8.3Hz,1H),3.83(s,2H),3.26-3.21(m,2H),3.06(d,J＝12.9Hz,1H),2.17(s,3H),2.14-1.93(m,4H),1.51(d,J＝6.0Hz,3H)；ESI-MS m/z:508.1[M+H] +。
实施例19 1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-((4-甲基噻唑-2-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物19)的合成
Figure PCTCN2020098775-appb-000051
以4-((3-氟-6-((4-甲基噻唑-2-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯盐酸盐和1-(溴甲基-d2)-3-氯-2-氟苯为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,CD 3OD)δ:7.76(t,J＝8.7Hz,1H),7.73-7.57(m,3H),7.22(dd,J＝8.8,2.9Hz,1H),6.58(s,1H),3.92(s,2H),3.44-3.31(m,2H),3.16(m,1H),2.19(s,3H),2.15-1.86(m,4H),1.51(m,3H)；ESI-MS m/z:510.0[M+H] +。
实施例20 1-(3-氯-2-氟苄基)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2,2-二甲基哌啶-4-羧酸(化合物20)的合成
Figure PCTCN2020098775-appb-000052
以1-(叔丁基)4-甲基4-((6-溴-3-氟吡啶-2-基)甲基)-2,2-双甲基哌啶-1,4-双甲酸酯和2-氨基噻唑为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,CD 3OD)δ:7.76(t,J＝8.7Hz,1H),7.70-7.51(m,3H),7.35-7.24(m,2H),7.18(dd,J＝8.8,2.9Hz,1H),4.61(d,J＝13.3Hz,1H),4.32(dd,J＝13.6,8.3Hz,1H)，3.94(s,2H),3.34-3.22(m,2H),2.31(s，2H),2.02-1.81(m,2H),1.45(s,6H)；ESI-MS m/z:508.2[M+H] +。
实施例21 1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-(噻唑-2-基氨基)吡啶-2-基)甲基)-2,2-二甲基哌啶-4-羧酸(化合物21)的合成
Figure PCTCN2020098775-appb-000053
以1-(叔丁基)4-甲基4-((6-溴-3-氟吡啶-2-基)甲基)-2,2-双甲基哌啶-1,4-双甲酸酯和2-氨基噻唑为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,CD 3OD)δ:7.75(t,J＝8.7Hz,1H),7.70-7.55(m,3H),7.37-7.26(m,2H),7.20(dd,J＝8.8,2.9Hz,1H),3.96(s,2H),3.57-3.44(m,2H),2.32(s，2H),2.02-1.85(m,2H),1.43(s,6H)；ESI-MS m/z:509.2[M+H] +。
实施例22 1-(3-氯-2-氟苯甲酰基)-4-((3-氟-6-((5-甲基-1H-吡唑-3-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物22)的合成
Figure PCTCN2020098775-appb-000054
4-((6-溴-3-氟吡啶-2-基)甲基)-1-(3-氯-2-氟苯甲酰基)-2-甲基哌啶-4-羧酸甲酯：
100mL单口瓶中加入3-氯-2-氟苯甲酸(262mg,1.50mmol)，DMF(20mL)，EDCI(431mg，2.25mmol)，HOBt(304mg,2.25mmol)和DIPEA(970mg，7.52mmol)，混合液Ar保护下室温搅拌30min，后加入4-((6-溴-3-氟吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯(345mg,1.0mmol)，体系室温搅拌20h。LC-MS监测反应完成后，体系加水(40mL)淬灭，EA(50mL*2)萃取，合并有机相用饱和氯化钠溶液洗涤，浓缩，残留物柱层析纯化得4-((6-溴-3-氟吡啶-2-基)甲基)-1-(3-氯-2-氟苯甲酰基)-2-甲基哌啶-4-羧酸甲酯(426mg，收率85％)。ESI-MS m/z:501.1/503.1[M+H] +。
1-(3-氯-2-氟苯甲酰基)-4-((3-氟-6-((5-甲基-1H-吡唑-3-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸
100mL单口瓶中加入4-((6-溴-3-氟吡啶-2-基)甲基)-1-(3-氯-2-氟苯甲酰基)-2-甲基哌啶-4-羧酸甲酯(426mg,0.85mmol)，1-Boc-5-甲基-3-氨基吡唑(201mg,1.02mmol)，Pd 2(dba) 3(92mg,0.10mmol)，Xantphos(116mg,0.20mmol)，K 3PO 4(96mg，0.45mmol)和1,4-dioxane(10mL)，Ar保护下升温至100℃反应约5h。LC/MS检测反应完全。粗品柱层析纯化(PE/EA＝10/1to 5/1)得黄色泡状固体4-((6–((1-(叔丁氧基羰基)-5-甲基-1H-吡唑-3-基)氨基)-3-氟吡啶-2-基)甲基)-1-(3-氯-2-氟苯甲酰基)-2-甲基哌啶-4-羧酸甲酯(394，收率75％)，ESI-MS m/z:618.1[M+H] +。
以上述中间体为原料，采用实施例1中的合成方法得到目标化合物。
1H NMR(400MHz,CD 3OD)δ:7.65(dt,J＝16.0,8.4Hz,3H),7.35(t,J＝7.9Hz,1H),6.92(dd,J＝9.0,3.1Hz,1H),6.14-6.05(m,1H),3.93(dd,J＝11.5,6.1Hz,1H),2.57-2.49(m,3H),2.40(s,3H),2.23-2.00(m,4H),1.61-1.48(m,3H)；ESI-MS m/z:504.2[M+H] +。
实施例23 1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-((5-甲基-1H-吡唑-3-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物23)的合成
Figure PCTCN2020098775-appb-000055
4-((6-溴-3-氟吡啶-2-基)甲基)-1-((3-氯-2-氟苯基)甲基-d2)-2-甲基哌啶-4-甲酸甲酯
100mL单口瓶中加入4-((6-溴-3-氟吡啶-2-基)甲基)-2-甲基哌啶-4-甲酸甲酯(1g,2.62mmol，参照专利WO2016077161中的方法合成得到)，1-(溴甲基-d2)-3-氯-2-氟苯(650mg,2.88mmol)，K 2CO 3(1.811g,13.1mmol)，KI(10mg)和ACN(20mL)，室温反应约2h。LC/MS检测反应完全。反应液浓缩干，柱层析纯化(PE/EA＝20/1to 8/1)得无色油状4-((6-溴-3-氟吡啶-2-基)甲基)-1-((3-氯-2-氟苯基)甲基-d2)-2-甲基哌啶-4-甲酸甲酯(985mg，收率77％)，ESI-MS m/z:489.1/491.1[M+H] +。
4-((6-((1-(叔丁氧羰基)-5-甲基-1H-吡唑-3-基)氨基)-3-氟吡啶-2-基)甲基)-1-((3-氯-2-氟苯基)甲基-d2)-2-甲基哌啶-4-甲酸甲酯
100mL单口瓶中加入4-((6-溴-3-氟吡啶-2-基)甲基)-1-((3-氯-2-氟苯基)甲基-d2)-2-甲基哌啶-4-甲酸甲酯(985mg,2.01mmol)，1-Boc-5-甲基-3-氨基吡唑(476mg,2.41mmol)，Pd 2(dba) 3(92mg,0.10mmol)，Xantphos(116mg,0.20mmol)，K 3PO 4(1.067mmol)和1,4-dioxane(20mL)，Ar保护下升温至100℃反应约5h。LC-MS检测反应完全。粗品柱层析纯化(PE/EA＝10/1to 5/1)得黄色泡状固体4-((6-((1-(叔丁氧羰基)-5-甲基-1H-吡唑-3-基)氨基)-3-氟吡啶-2-基)甲基)-1-((3-氯-2-氟苯基)甲基-d2)-2-甲基哌啶-4-甲酸甲酯(1.03g，收率84％)，ESI-MS m/z:605.3[M+H] +。
1-((3-氯-2-氟苯基)甲基-d2)-4-((3-氟-6-((5-甲基-1H-吡唑-3-基)氨基)吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸
100mL单口瓶中加入4-((6-((1-(叔丁氧羰基)-5-甲基1H-吡唑-3-基)氨基)-3-氟吡啶-2-基)甲基)-1-((3-氯-2-氟苯基)甲基-d2)-2-甲基哌啶-4-甲酸甲酯(1.03g,1.70mmol)，水(15mL)，浓HCl(15mL)，105℃回流反应约5h。LC-MS检测反应完全，将反应液减压浓缩至干，残留物加ACN(30mL)室温打浆，抽滤，滤饼用ACN(5mL*2)洗涤，晾干得淡黄 色粉末状固体(844mg，收率88％)。
1H NMR(400MHz,CD 3OD)δ:7.63(dt,J＝16.0,8.4Hz,3H),7.32(t,J＝7.9Hz,1H),6.90(dd,J＝9.0,3.1Hz,1H),6.04-6.01(m,1H),3.96(dd,J＝11.5,6.1Hz,1H),3.58-3.30(m,4H),2.40(s,3H),2.23-2.00(m,5H),1.61-1.48(m,3H)；ESI-MS m/z:492.2[M+H] +。
实施例24 1-(3-氯-2-氟苄基)-4-((6-((5-环丙基-1H-吡唑-3-基)氨基)-3-氟吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸(化合物24)的合成
Figure PCTCN2020098775-appb-000056
以4-((6-溴-3-氟吡啶-2-基)甲基)-2-甲基哌啶-4-羧酸甲酯和1-(溴甲基)-3-氯-2-氟苯，以及3-氨基-5-环丙基-1H-吡唑-1-羧酸叔丁酯为原料，采用实施例23中的合成方法得到目标化合物。
1H NMR(400MHz,CD 3OD)δ:7.61(dt,J＝16.0,8.4Hz,3H),7.34(t,J＝7.9Hz,1H),6.85(dd,J＝9.0,3.1Hz,1H),6.01-5.95(m,1H),4.56(d,J＝13.3Hz,1H),4.13(dd,J＝13.6,8.3Hz,1H)，3.93(dd,J＝11.5,6.1Hz,1H),3.68-3.41(m,4H),2.23-2.00(m,4H),1.61-1.48(m,4H),0.85-0.67(m,4H)；ESI-MS m/z:516.2[M+H] +。
实施例25 Aurora激酶抑制活性的测试
上述化合物对于Aurora激酶活性在体外的抑制活性测定通过Caliper Mobility Shift Assay方法测定。化合物从10μM开始依次三倍稀释，总共得到10个浓度，先将酶和激酶反应液(20mM HEPES,pH 7.5,0.01％Triton X-100)混合后，加入梯度稀释的化合物。在室温孵育10分钟，让化合物和酶充分结合。然后加入FAM标记的多肽作为底物在25℃进行激酶反应，一定的时间后，加入终止液终止。然后采用Caliper读取转化率，换算成抑制率数据后边通过统计软件计算获得IC 50值，以不加药的溶剂空白作为阴性对照，以LY-3295668作为阳性对照。上述各化合物的结果列于表2中。
实施例26 H1975细胞抗增殖活性的测试
把对数生长期的肿瘤(肺癌H1975)细胞消化后，吹打成单细胞悬液，分别接种于384孔培养板；每孔5×10 3个细胞，每孔加入培养基50μL，37℃，5％CO 2培养箱中培养过 夜。待细胞贴壁后，分别加入适当浓度的受试化合物和阳性对照药物，配置五种不同浓度的样品，以空白组为阴性对照组，在培养箱中再培养72h。然后，每孔加入50ul CTL plus,通过测量细胞中ATP的含量评价细胞的数量。用GRAPHPAD进行拟合，计算IC 50，结果列于表2中。
表2.本发明部分化合物对Aurora激酶活性和对H1975细胞的抗增殖活性
Figure PCTCN2020098775-appb-000057
以上数据说明通式(1)化合物中，当-L-基团从CH 2改变成适当大小的基团所取代，比如CD 2，和/或者，当W是
Figure PCTCN2020098775-appb-000058
基团时，化合物具有极强的Aurora-A激酶活性，同时Aurora-B激酶活性和H1975细胞抗增殖活性得到大幅提高。本发明化合物的各光学异构体活性具有区别，化合物1-1活性比消旋化合物1活性更强一些，本发明其它化合物的各光学异构体的活性可以通过相同方法进行测试，其中也会有活性更好的光学活性异构体。
实施例27 小鼠体内抗肿瘤活性评价
人肺癌H1975细胞用含10％胎牛血清的1640于37℃、5％CO 2培养箱中常规培养，传代后，待细胞达到所需量时，消化收集细胞。将8×10 6个H1975细胞注射入每只裸小鼠左侧腋下，待肿瘤生长至80mm 3后，将动物随机分组开始给药。分别为1)溶剂对照组，6只；2)LY-3295668组、化合物13组和化合物23组，每组6只。溶剂对照组每天一次灌胃5％DMSO+45％PEG400+50％水的溶剂；LY-3295668组、化合物13组和化合物23组灌胃6mg/mL的化合物溶液0.1mL/10g(60mg/kg/day)。每两天测定肿瘤体积，测 量小鼠体重，于给药第21天处死裸小鼠。计算相对肿瘤体积(RTV)、相对肿瘤增值率(T/C)和肿瘤生长抑制率，并进行统计学检测。试验结果见下表3。
表3化合物对人非小细胞肺腺癌NCI-H1975裸小鼠移植瘤的实验治疗作用
Figure PCTCN2020098775-appb-000059
与对照相比*:P<0.05，**:P<0.01，***:P<0.001，****：P<0.0001；D1:开始给药时间；D21:结束给药时间；qd*21：给药21天，每天给药一次。RTV:相对肿瘤体积，计算公式为：RTV＝V t/V 0。T/C(％)＝T RTV/C RTV X 100。T RTV:为治疗组RTV；C RTV:为阴性对照组RTV。TGI(％)：肿瘤生长抑制率(％)。疗效评价标准:T/C(％)>60为无效；T/C(％)≤60,并经统计学处理P<0.05为有效.
从上表3可以看出，化合物13和阳性对照LY-3295668相比，体内抗肿瘤活性明显增强，说明通式(1)化合物中，当-L-基团从CH 2改变成适当大小的基团所取代，比如CD 2，和/或者，当W是
Figure PCTCN2020098775-appb-000060
基团时，化合物的体内抗肿瘤活性得到大幅提高。这对靶向极光激酶治疗肿瘤具有重要的意义。
实施例28 小鼠体内NCI-H69模型抗肿瘤活性评价
人肺癌NCI-H69细胞用含10％胎牛血清的1640于37℃、5％CO 2培养箱中常规培养，传代后，待细胞达到所需量时，消化收集细胞。将1×10 7个H69细胞注射入每只裸小鼠左侧背下，待肿瘤生长至290mm 3左右，将动物随机分组开始给药。分别为1)溶剂对照组，8只；2)LY-3295668组、化合物1-1低剂量组、化合物1-1中剂量组和化合物1-1高剂量组每组8只。溶剂对照组每天两次灌胃0.5％MC的溶剂；LY-3295668 组、化合物1-1低剂量组、化合物1-1中剂量组和化合物1-1高剂量组灌胃化合物溶液0.1mL/10g(每天两次)。每两天测定肿瘤体积，测量小鼠体重，于给药第21天处死裸小鼠。计算相对肿瘤体积(RTV)、相对肿瘤增值率(T/C)和肿瘤生长抑制率，并进行统计学检测。试验结果见下表4。
表4化合物对人肺癌NCI-H69裸小鼠移植瘤的实验治疗作用
Figure PCTCN2020098775-appb-000061
与对照相比*:P<0.05，**:P<0.01，***:P<0.001，****：P<0.0001；D1:开始给药时间；D21:结束给药时间；bid*21：给药21天，每天给药两次，给药间隔12小时。RTV:相对肿瘤体积，计算公式为：RTV＝V t/V 0。T/C(％)＝T RTV/C RTV X 100。T RTV:为治疗组RTV；C RTV:为阴性对照组RTV。TGI(％)：肿瘤生长抑制率(％)。疗效评价标准:T/C(％)>60为无效；T/C(％)≤60,并经统计学处理P<0.05为有效.
从上表4可以看出，化合物1-1和阳性对照LY-3295668相比，对NCI-H69模型小鼠的体内抗肿瘤活性更强，且药效呈剂量关系。
虽然以上描述了本发明的具体实施方式，但是本领域的技术人员应当理解，这些仅 是举例说明，在不背离本发明的原理和实质的前提下，可以对这些实施方式做出多种变更或修改。因此，本发明的保护范围由所附权利要求书限定。

Claims (9)

  1. 一种结构如通式(1)所示的化合物或其各光学异构体、各晶型、药学上可接受的盐：
    Figure PCTCN2020098775-appb-100001
    式(1)中：
    R 1为芳基、杂芳基、
    Figure PCTCN2020098775-appb-100002
    所述芳基或杂芳基可被1-3个下述基团所取代：卤素、C1-C3烷基、C1-C3烷氧基、卤素取代C1-C3烷基和卤素取代C1-C3烷氧基；
    R 2为H或甲基；
    R 3为H或F；
    W为
    Figure PCTCN2020098775-appb-100003
    其中R a为H、C1-C3烷基或C3-C6环烷基，R b为H、C1-C3烷基或C3-C6环烷基；和
    L为CH 2、CO、CD 2、CH(Me)、C(Me) 2、
    Figure PCTCN2020098775-appb-100004
    当W为
    Figure PCTCN2020098775-appb-100005
    Figure PCTCN2020098775-appb-100006
    且R b为H、C2-C3烷基或C3-C6环烷基时；或L为CO、CD 2、CHMe、C(Me) 2、
    Figure PCTCN2020098775-appb-100007
    当W为
    Figure PCTCN2020098775-appb-100008
    且R b为甲基时。
  2. 如权利要求1所述的化合物，其中所述式(1)中，R 1为
    Figure PCTCN2020098775-appb-100009
    Figure PCTCN2020098775-appb-100010
    其中X为NH、O或S，R c和R d独立为H、卤素、C1-C3烷基、C1-C3烷氧基、卤素取代C1-C3烷基或卤素取代C1-C3烷氧基。
  3. 如权利要求2所述的化合物，其中所述式(1)中，R 1为
    Figure PCTCN2020098775-appb-100011
    Figure PCTCN2020098775-appb-100012
  4. 如权利要求1所述的化合物，其中所述式(1)中，
    W为下列基团：
    Figure PCTCN2020098775-appb-100013
    Figure PCTCN2020098775-appb-100014
    L为CH 2、CO、CD 2、CH(Me)、C(Me) 2、
    Figure PCTCN2020098775-appb-100015
    当W为
    Figure PCTCN2020098775-appb-100016
    Figure PCTCN2020098775-appb-100017
    Figure PCTCN2020098775-appb-100018
    时；或L为CO、CD 2、CHMe、C(Me) 2、
    Figure PCTCN2020098775-appb-100019
    当W为
    Figure PCTCN2020098775-appb-100020
    时。
  5. 如权利要求1-4所述的化合物，或其一种药学上可接受的盐，其中所述化合物具有以下结构之一：
    Figure PCTCN2020098775-appb-100021
    Figure PCTCN2020098775-appb-100022
  6. 以权利要求1-5中任一项所述的化合物、或其各光学异构体、各晶型、药学上可 接受的盐作为有效成分的极光激酶抑制剂。
  7. 药物组合物，其特征在于：权利要求1-5中任一项所述的化合物作为有效成分，并含有可药用载体或稀释剂。
  8. 一种权利要求1-5任一项所述的化合物、或其各光学异构体、各晶型、药学上可接受的盐的用途，其特征在于，作为极光激酶抑制剂在抗肿瘤药物制备中的用途。
  9. 一种权利要求1-5任一项所述的化合物、或其各光学异构体、各晶型、药学上可接受的盐的用途，其特征在于，在抗肿瘤药物制备中的用途。
PCT/CN2020/098775 2019-07-16 2020-06-29 极光激酶抑制剂及其用途 WO2021008338A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2021013981A MX2021013981A (es) 2019-07-16 2020-06-29 Inhibidores de la cinasa aurora y usos de los mismos.
BR112021023765A BR112021023765A2 (pt) 2019-07-16 2020-06-29 Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto
EP20840146.3A EP4001276A4 (en) 2019-07-16 2020-06-29 AURORA KINASE INHIBITOR AND USE THEREOF
CN202080005314.4A CN114072400B (zh) 2019-07-16 2020-06-29 极光激酶抑制剂及其用途
AU2020314910A AU2020314910A1 (en) 2019-07-16 2020-06-29 Aurora kinase inhibitor and use thereof
JP2022502476A JP2022541467A (ja) 2019-07-16 2020-06-29 オーロラキナーゼ阻害剤およびその使用
KR1020217036790A KR20220035031A (ko) 2019-07-16 2020-06-29 오로라 키나아제 억제제 및 이의 용도
CA3142069A CA3142069A1 (en) 2019-07-16 2020-06-29 Aurora kinase inhibitor and use thereof
US17/200,854 US20210198261A1 (en) 2019-07-16 2021-03-14 Aurora kinase inhibitors and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910643061.2 2019-07-16
CN201910643061.2A CN112239465A (zh) 2019-07-16 2019-07-16 极光激酶抑制剂及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/200,854 Continuation US20210198261A1 (en) 2019-07-16 2021-03-14 Aurora kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
WO2021008338A1 true WO2021008338A1 (zh) 2021-01-21

Family

ID=74166907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/098775 WO2021008338A1 (zh) 2019-07-16 2020-06-29 极光激酶抑制剂及其用途

Country Status (10)

Country Link
US (1) US20210198261A1 (zh)
EP (1) EP4001276A4 (zh)
JP (1) JP2022541467A (zh)
KR (1) KR20220035031A (zh)
CN (2) CN112239465A (zh)
AU (1) AU2020314910A1 (zh)
BR (1) BR112021023765A2 (zh)
CA (1) CA3142069A1 (zh)
MX (1) MX2021013981A (zh)
WO (1) WO2021008338A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021147974A1 (en) * 2020-01-22 2021-07-29 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic compounds useful as aurora a selective inhibitors
WO2023005957A1 (en) * 2021-07-28 2023-02-02 Jacobio Pharmaceuticals Co., Ltd. Polymorphic forms of aurora a selective inhibitors and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
CN104159893A (zh) * 2012-02-29 2014-11-19 大鹏药品工业株式会社 新型哌啶化合物或其盐
US20150065479A1 (en) * 2013-08-27 2015-03-05 Taiho Pharmaceutical Co., Ltd. Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
WO2016077161A1 (en) 2014-11-14 2016-05-19 Eli Lilly And Company Aurora a kinase inhibitor
WO2018117267A1 (ja) * 2016-12-22 2018-06-28 大鵬薬品工業株式会社 置換ピペリジン化合物の塩

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
CN104159893A (zh) * 2012-02-29 2014-11-19 大鹏药品工业株式会社 新型哌啶化合物或其盐
US20150065479A1 (en) * 2013-08-27 2015-03-05 Taiho Pharmaceutical Co., Ltd. Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
WO2016077161A1 (en) 2014-11-14 2016-05-19 Eli Lilly And Company Aurora a kinase inhibitor
CN107108567A (zh) * 2014-11-14 2017-08-29 伊莱利利公司 极光激酶a抑制剂
WO2018117267A1 (ja) * 2016-12-22 2018-06-28 大鵬薬品工業株式会社 置換ピペリジン化合物の塩

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CANCER METASTASIS REV., vol. 22, 2003, pages 451
CAREYSUNDBERG: "ADVANCED ORGANIC CHEMISTRY", vol. A, B, 2000, PLENUM
GREENWUTS: "PROTECTIVE GROUPS IN ORGANIC SYNTHESIS", 1999, WILEY
J. CELL SCI., vol. 120, 2007, pages 2987
J. CLIN. PATHOL., vol. 60, no. 2, 2007, pages 218 - 221
MOL. CANCER THER., vol. 8, 2009, pages 2046 - 2056
NAT. REV. CANCER, vol. 5, 2005, pages 42
PROC NATL ACAD SCI USA, vol. 99, no. 24, 2002, pages 15440 - 15445
VASILEVICH, NATALYA I. ET AL.: "General Ser/Thr Kinases Pharmacophore Approach for Selective Kinase Inhibitors Search as Exemplified by Design of Potent and Selective Aurora A Inhibitors", CHEM BIOL DRUG DES, vol. 88, no. 1,, 30 January 2016 (2016-01-30), XP055598572, ISSN: 1747-0285, DOI: 20200715161259X *
VASILEVICH, NATALYA I. ET AL.: "Search for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model", PHARMACEUTICALS, vol. 9, no. 2,, 13 April 2016 (2016-04-13), XP055774024, ISSN: 1424-8247, DOI: 20200715161758X *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021147974A1 (en) * 2020-01-22 2021-07-29 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic compounds useful as aurora a selective inhibitors
US11384066B1 (en) 2020-01-22 2022-07-12 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic compounds useful as aurora a selective inhibitors
AU2021209744B2 (en) * 2020-01-22 2023-08-31 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic compounds useful as Aurora A selective inhibitors
EP4093736A4 (en) * 2020-01-22 2024-01-10 Jacobio Pharmaceuticals Co Ltd NOVEL HETEROCYCLIC COMPOUNDS AS AURORA-SELECTIVE INHIBITORS
WO2023005957A1 (en) * 2021-07-28 2023-02-02 Jacobio Pharmaceuticals Co., Ltd. Polymorphic forms of aurora a selective inhibitors and uses thereof

Also Published As

Publication number Publication date
CN114072400B (zh) 2023-04-07
JP2022541467A (ja) 2022-09-26
CN112239465A (zh) 2021-01-19
EP4001276A4 (en) 2023-09-13
EP4001276A1 (en) 2022-05-25
AU2020314910A1 (en) 2022-01-27
MX2021013981A (es) 2022-01-18
CA3142069A1 (en) 2021-01-21
BR112021023765A2 (pt) 2022-01-25
CN114072400A (zh) 2022-02-18
US20210198261A1 (en) 2021-07-01
KR20220035031A (ko) 2022-03-21

Similar Documents

Publication Publication Date Title
WO2021129824A1 (zh) 新型K-Ras G12C抑制剂
CN101657443B (zh) 作为白三烯生物合成抑制剂的[1,2,3]三唑取代的喹啉和香豆素
CN113544128A (zh) Kras-g12c抑制剂
JP4667537B2 (ja) アシルチオウレア化合物又はその塩、及びその用途
WO2015140133A1 (en) Piperidine-dione derivatives
UA111754C2 (uk) Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2949357T3 (es) Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos
WO2021008338A1 (zh) 极光激酶抑制剂及其用途
CN118055933A (zh) 选择性parp1抑制剂及其应用
CN103249733A (zh) 用于治疗或预防轻度认知障碍的稠合的三唑
WO2020224626A1 (zh) 用作激酶抑制剂的化合物及其应用
AU2019230859B2 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
WO2015057200A1 (en) Heteroaryl linked quinolinyl modulators of rorϒt
WO2021110009A1 (zh) 新型极光激酶抑制剂及其用途
WO2010131738A1 (ja) アゼチジン化合物およびその医薬用途
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
CN114763360A (zh) 手性大环化合物作为蛋白激酶抑制剂及其用途
JP5760005B2 (ja) 新規（複素環／テトラヒドロピリジン）−（ピペラジニル）−１−アルカノンおよび（複素環／ジヒドロピロリジン）−（ピペラジニル）−１−アルカノン誘導体、並びにｐ７５阻害剤としてのこれらの使用
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物
WO2022174796A1 (zh) 作为Wee-1抑制剂的嘧啶化合物
WO2022228512A1 (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20840146

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3142069

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021023765

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022502476

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 112021023765

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211125

ENP Entry into the national phase

Ref document number: 2020314910

Country of ref document: AU

Date of ref document: 20200629

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020840146

Country of ref document: EP

Effective date: 20220216